New pharmacological avenues for the treatment of l-DOPA-induced dyskinesias in Parkinson's disease

Targeting glutamate and adenosine receptors

Fabio Blandini, Marie Therese Armentero

Research output: Contribution to journalArticle

47 Citations (Scopus)

Abstract

Introduction: Parkinson's disease (PD) therapy is still centered on the use of l-3,4-dihydroxyphenylalanine (l-DOPA), which is hampered by numerous side effects, including abnormal involuntary movements known as l-DOPA-induced dyskinesias (LIDs). LIDs are the result of pre-and postsynaptic changes at the corticostriatal level, induced by chronic and pulsatile stimulation of striatal dopaminergic receptors. These changes impact on synaptic plasticity and involve also selected, nondopaminergic receptors expressed by striatal projection neurons. Areas covered: Among nondopaminergic receptors, glutamate receptors NMDA and mGluR5 subtypes in particular and adenosine A2A receptors are those most likely involved in LIDs. The aim of the present review is to summarize results of studies undertaken with specific antagonists of these receptors, first conducted in animal models of LIDs, which in selected cases have been translated into clinical trials. Expert opinion: Selected antagonists of glutamate and adenosine receptors have been proposed as anti-dyskinetic agents. Promising results have been obtained in preclinical investigations and in initial clinical trials, but long-term safety, tolerability and efficacy studies in patients are still required. The current development of novel antagonists, including tools able to act on receptor mosaics, may provide innovative tools for LIDs management in the next future.

Original languageEnglish
Pages (from-to)153-168
Number of pages16
JournalExpert Opinion on Investigational Drugs
Volume21
Issue number2
DOIs
Publication statusPublished - Feb 2012

Fingerprint

Dihydroxyphenylalanine
Purinergic P1 Receptors
Dyskinesias
Glutamate Receptors
Parkinson Disease
Pharmacology
Corpus Striatum
Therapeutics
Clinical Trials
Adenosine A2A Receptors
Purinergic P1 Receptor Antagonists
Excitatory Amino Acid Antagonists
Neuronal Plasticity
Expert Testimony
N-Methylaspartate
Animal Models
Safety
Neurons

Keywords

  • Adenosine
  • Dyskinesias
  • Glutamate
  • l-DOPA
  • MGluR5
  • NMDA
  • Parkinson's disease

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

@article{f34f8bd685f944ab9bccc55706257dc1,
title = "New pharmacological avenues for the treatment of l-DOPA-induced dyskinesias in Parkinson's disease: Targeting glutamate and adenosine receptors",
abstract = "Introduction: Parkinson's disease (PD) therapy is still centered on the use of l-3,4-dihydroxyphenylalanine (l-DOPA), which is hampered by numerous side effects, including abnormal involuntary movements known as l-DOPA-induced dyskinesias (LIDs). LIDs are the result of pre-and postsynaptic changes at the corticostriatal level, induced by chronic and pulsatile stimulation of striatal dopaminergic receptors. These changes impact on synaptic plasticity and involve also selected, nondopaminergic receptors expressed by striatal projection neurons. Areas covered: Among nondopaminergic receptors, glutamate receptors NMDA and mGluR5 subtypes in particular and adenosine A2A receptors are those most likely involved in LIDs. The aim of the present review is to summarize results of studies undertaken with specific antagonists of these receptors, first conducted in animal models of LIDs, which in selected cases have been translated into clinical trials. Expert opinion: Selected antagonists of glutamate and adenosine receptors have been proposed as anti-dyskinetic agents. Promising results have been obtained in preclinical investigations and in initial clinical trials, but long-term safety, tolerability and efficacy studies in patients are still required. The current development of novel antagonists, including tools able to act on receptor mosaics, may provide innovative tools for LIDs management in the next future.",
keywords = "Adenosine, Dyskinesias, Glutamate, l-DOPA, MGluR5, NMDA, Parkinson's disease",
author = "Fabio Blandini and Armentero, {Marie Therese}",
year = "2012",
month = "2",
doi = "10.1517/13543784.2012.651457",
language = "English",
volume = "21",
pages = "153--168",
journal = "Expert Opinion on Investigational Drugs",
issn = "1354-3784",
publisher = "Informa Healthcare",
number = "2",

}

TY - JOUR

T1 - New pharmacological avenues for the treatment of l-DOPA-induced dyskinesias in Parkinson's disease

T2 - Targeting glutamate and adenosine receptors

AU - Blandini, Fabio

AU - Armentero, Marie Therese

PY - 2012/2

Y1 - 2012/2

N2 - Introduction: Parkinson's disease (PD) therapy is still centered on the use of l-3,4-dihydroxyphenylalanine (l-DOPA), which is hampered by numerous side effects, including abnormal involuntary movements known as l-DOPA-induced dyskinesias (LIDs). LIDs are the result of pre-and postsynaptic changes at the corticostriatal level, induced by chronic and pulsatile stimulation of striatal dopaminergic receptors. These changes impact on synaptic plasticity and involve also selected, nondopaminergic receptors expressed by striatal projection neurons. Areas covered: Among nondopaminergic receptors, glutamate receptors NMDA and mGluR5 subtypes in particular and adenosine A2A receptors are those most likely involved in LIDs. The aim of the present review is to summarize results of studies undertaken with specific antagonists of these receptors, first conducted in animal models of LIDs, which in selected cases have been translated into clinical trials. Expert opinion: Selected antagonists of glutamate and adenosine receptors have been proposed as anti-dyskinetic agents. Promising results have been obtained in preclinical investigations and in initial clinical trials, but long-term safety, tolerability and efficacy studies in patients are still required. The current development of novel antagonists, including tools able to act on receptor mosaics, may provide innovative tools for LIDs management in the next future.

AB - Introduction: Parkinson's disease (PD) therapy is still centered on the use of l-3,4-dihydroxyphenylalanine (l-DOPA), which is hampered by numerous side effects, including abnormal involuntary movements known as l-DOPA-induced dyskinesias (LIDs). LIDs are the result of pre-and postsynaptic changes at the corticostriatal level, induced by chronic and pulsatile stimulation of striatal dopaminergic receptors. These changes impact on synaptic plasticity and involve also selected, nondopaminergic receptors expressed by striatal projection neurons. Areas covered: Among nondopaminergic receptors, glutamate receptors NMDA and mGluR5 subtypes in particular and adenosine A2A receptors are those most likely involved in LIDs. The aim of the present review is to summarize results of studies undertaken with specific antagonists of these receptors, first conducted in animal models of LIDs, which in selected cases have been translated into clinical trials. Expert opinion: Selected antagonists of glutamate and adenosine receptors have been proposed as anti-dyskinetic agents. Promising results have been obtained in preclinical investigations and in initial clinical trials, but long-term safety, tolerability and efficacy studies in patients are still required. The current development of novel antagonists, including tools able to act on receptor mosaics, may provide innovative tools for LIDs management in the next future.

KW - Adenosine

KW - Dyskinesias

KW - Glutamate

KW - l-DOPA

KW - MGluR5

KW - NMDA

KW - Parkinson's disease

UR - http://www.scopus.com/inward/record.url?scp=84855814440&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84855814440&partnerID=8YFLogxK

U2 - 10.1517/13543784.2012.651457

DO - 10.1517/13543784.2012.651457

M3 - Article

VL - 21

SP - 153

EP - 168

JO - Expert Opinion on Investigational Drugs

JF - Expert Opinion on Investigational Drugs

SN - 1354-3784

IS - 2

ER -